Therapeutic plasmapheresis may remove platelets as well as plasma. Unintent
ional platelet loss, if not recognized, may lead to inappropriate patient a
ssessment and treatment. A patient with thrombotic thrombocytopenic purpura
hemolytic uremic syndrome (TTP-HUS) is reported in whom persistent thromboc
ytopenia was interpreted as continuing active disease; thrombocytopenia res
olved only after plasma exchange treatments were stopped. This observation
prompted a systematic study of platelet loss with plasmapheresis. Data are
reported on platelet loss during 432 apheresis procedures in 71 patients wi
th six disease categories using three different instruments. Comparing the
first procedure recorded for each patient, there was a significant differen
ce among instrument types (P < 0.001); platelet loss was greater with the F
resenius AS 104 (17.5%, N = 21) than with the COBE Spectra (1.6%. N = 26) o
r the Haemonetics LN9000 (2.6%, N = 24). With all procedures, platelet loss
ranged from 0 to 71%. Among disease categories, platelet loss was greater
in patients with dysproteinemias who were treated for hyperviscosity sympto
ms. Absolute platelet loss with the first recorded apheresis procedure, in
the 34 patients who had a normal platelet count before the procedure, was a
lso greater with the AS 104 (2.23 x 10(11) platelets) than with the Spectra
(0.29 x 10(11) platelets) or the LN9000 (0.37 x 10(11) platelets). In 39 p
atients in whom data were collected on consecutive days, platelet removal b
y plasmapheresis correlated with a decreased patient platelet count (r = 0.
40, P = 0.011). In these 39 patients, the platelet counts were significantl
y decreased at 24 hours (P = 0.002).J. Clin. Apheresis. 16:55-60, 2001. (C)
2001 Wiley-Liss, Inc.